|Articles|March 15, 2014

BioPharm International-03-15-2014
Volume 2014 eBook
Issue 1

An Environmental Lifecycle Assessment of Single-Use and Conventional Process Technology: Comprehensive Environmental Impacts

Author(s)William Flanagan, Andrew Brown, Matthew Pietrzykowski

An environmental study of single-use process technology for biopharmaceutical manufacturing offers a comprehensive examination of environmental impacts across the full process train using lifecycle assessment.

Read

BioPharm International’s 2014 Single-Use Systems

eBook.

Articles in this issue

over 12 years ago

Article

Achieving Supply Chain Excellence in Single-Use Systems

over 12 years ago

Article

Innovation in Pre-packed Disposable Chromatography Columns

over 12 years ago

Article

Single-Use Technology in Downstream Processing

over 12 years ago

Article

Configuring Manufacturing Operation Management Applications

over 12 years ago

Article

Single-Use Technology for Syringe Filling

Newsletter

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe

Related to this article

Close-up of an older person's hands, with the thumb of one hand pressing into the palm of the other, against a blurred teal background. | Image Credit: © eyepark - stock.adobe.com

October 2nd, 2026

Artiva to Present AlloNK Data Showing CAR T-Like B-Cell Depletion in Rheumatologic Diseases at ACR 2026

Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.

Tablet, science team and people learning for cancer cure, help or medical development in laboratory. Training, investigation or research info with scientists in clinical trial for medicine internship | Image credit: © CoetzeeRising/peopleimages.com - © CoetzeeRising/peopleimages.com - stock.adobe.com

October 2nd, 2026

CaseBioscience Joins $7.3 Million ARPA-H Team on Cell Preservation

The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.

FDA - US Food and Drug Administration | Image credit: © gguy - © gguy - stock.adobe.com

October 1st, 2026

FDA Warns Fresenius Kabi Over Sterile Injectable Contamination

Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.

Close up dermatitis on skin, ill allergic rash eczema skin of patient , atopic dermatitis symptom skin detail texture , Fungus of skin ,The concept dermatology, treatment fungal | Image credit: © InfiniteStudio - © InfiniteStudio - stock.adobe.com

September 30th, 2026

Lilly's Lebrikizumab Improves Hand-Foot Atopic Dermatitis

More than half of patients achieved clear or almost clear hands and feet with lebrikizumab by week 16, and 77% reported satisfaction with clearance.

Regenerative medicine and therapeutic stem cell therapy to regrow damaged cells as treatment for disease as multicellular organisms for cellular treatment of injury or arthritis illness due to aging | Image credit: © freshidea - © freshidea - stock.adobe.com

September 29th, 2026

iRegene's NouvSight001 Cleared for US and China RP Trials

NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.

Brain imaging scan showing a cross-section of the human brain. | Image Credit: © merydolla - stopck.adobe.com

September 29th, 2026

uniQure's AMT-130 Shows Continued Slowing of Huntington's Disease at 48 Months, Though Primary Endpoint Misses Significance

Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.

Lower back pain | Image credit: © BigBlueStudio - © BigBlueStudio - stock.adobe.com

September 25th, 2026

J&J's Guselkumab (Tremfya) Meets Endpoints in Axial PsA Trial

Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.

September 24th, 2026

BIIE Aims to Be a Global Immune Engineering Embassy

Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.